Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in…
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
July 02, 2025 03:00 ET Â | Source: Belite Bio, Inc -Â 500…
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
June 20, 2025 19:30 ET Â | Source: Structure Therapeutics Inc. SAN FRANCISCO,…
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
June 19, 2025 01:00 ET Â | Source: Addex Therapeutics Strong cash position…
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
June 18, 2025 01:00 ET Â | Source: Addex Therapeutics Geneva, Switzerland, June…
Draig Therapeutics Launches with $140 Million (107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric…
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
June 13, 2025 16:52 ET Â | Source: Vaxart, Inc. SOUTH SAN FRANCISCO,…
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025 16:01 ET Â | Source: Nurix Therapeutics, Inc. SAN FRANCISCO,…
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
June 13, 2025 09:00 ET Â | Source: RAPT Therapeutics, Inc. SOUTH SAN…